Clinical Outcome Research
REALIZE (CVL-865) - reported to be a non-sedating benzodiazepine
PI: Dr. Hamada Altalib, DO, MPH, FAES
This is a multi-center, randomized, active-treatment, open-label extension of CVL-865 as adjunctive therapy in adults with drug-resistant focal onset seizures. Patients with focal seizures for at least two years and a failure of two or more anti-seizure medications are eligible to participate in this study, which will last for 25 weeks with up to seven visits.
HUMAN EPILEPSY PROJECT 3: NEW-ONSET GENERALIZED EPILEPSY
PI: Dr. Hamada Altalib, DO, MPH, FAES
This is a study coordinated and funded by the Epilepsy Foundation through New York University, which aims to characterize the long-term natural history of patients who have been newly diagnosed with idiopathic generalized epilepsy. This study involves yearly visits and monthly check-ins, along with a daily electronic diary to track seizure frequency.
NORSE: (New-Onset Refractory Status Epilepticus)
The purpose of this study is to understand the cause of NORSE and create a biorepository of laboratory and biomarker assessments of blood and tissue. This study will continue for two years, including visits at three, six, 12, and 24 months post-discharge.
MEDTRONIC DEEP BRAIN STIMULATION THERAPY POST-APPROVAL STUDY
PI: Dr. David King-Stephens, FAAN(Neurology), FAES, MD
Deep brain stimulation (DBS) is a surgical treatment for patients with epilepsy, and the purpose of this post-approval study is to further evaluate the long-term safety and effectiveness of Medtronic DBS therapy for epilepsy on seizure reduction in newly implanted patients through three years of follow-up.
RAISE (Randomized in Status Epilepticus)
This study is sponsored by Marinus Pharmaceuicals and is a double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of intravenous ganaxolone in status epilepticus (SE). This study involves approximately two days of treatment and follow-ups for the next four weeks. The primary objective is to establish efficacy and safety of IV ganaxolone for the treatment of SE after failure of first-line benzodiazepines and two second-line IV AEDs.